Ota J, Ueda N, Kimoto Y, Tsukahara Y, Fujita M, Taguchi T, Okumura T, Tomita K, Kimura M
Jpn J Antibiot. 1985 Sep;38(9):2638-46.
A newly developed human immunoglobulin for intravenous use, SM-4300, purified by cold ethanol precipitation and ion exchange resin, has been studied in the surgery. SM-4300 has been evaluated clinically against inpatients with severe bacterial and/or fungal infections in the combined use with the antibiotics which were resistant to antibiotic therapy. Total number of 13 patients affected with various severe infections were treated with SM-4300. Clinical effects of SM-4300 were excellent in 2 cases, good in 6, fair in 3 and poor in 2. The efficacy rate was summarized as 61.5%. No subjective and objective clinical side effects and abnormal laboratory findings were observed. In conclusion, combination therapy with SM-4300 and antibiotics was considered to be safe and effective against severe bacterial and/or fungal infections in the surgery.
一种新研发的静脉用人免疫球蛋白SM - 4300,通过冷乙醇沉淀和离子交换树脂纯化,已在外科手术中进行了研究。SM - 4300已与对抗生素治疗耐药的抗生素联合用于治疗严重细菌和/或真菌感染的住院患者,并进行了临床评估。共有13例患有各种严重感染的患者接受了SM - 4300治疗。SM - 4300的临床效果为:2例优,6例良,3例中,2例差。有效率总结为61.5%。未观察到主观和客观的临床副作用以及实验室检查异常结果。总之,SM - 4300与抗生素联合治疗对外科手术中的严重细菌和/或真菌感染被认为是安全有效的。